OS analysis of patients with different short-term response and progression patterns of donafenib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: An exploratory subgroup analysis of ZGDH3

Category Primary study
JournalJournal of Clinical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: d1eb34fe931654c43bcd42dd9a4bd25491cb8dd4
First added on: Feb 19, 2025